An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy

The HER2 monoclonal antibody, Trastuzumab, is the current standard treatment for HER2+ cancers but resistance to therapy occurs. Here, the authors show that activation of the PKR/eIF2α-P pathway exhibits anti-tumor effects in HER2+ cancer and is required for the response to Trastuzumab.

Guardado en:

Detalles Bibliográficos
Autores principales:	Cedric Darini, Nour Ghaddar, Catherine Chabot, Gloria Assaker, Siham Sabri, Shuo Wang, Jothilatha Krishnamoorthy, Marguerite Buchanan, Adriana Aguilar-Mahecha, Bassam Abdulkarim, Jean Deschenes, Jose Torres, Josie Ursini-Siegel, Mark Basik, Antonis E. Koromilas
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/7ecf6c59b1264893ab9910b75de10e72
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7ecf6c59b1264893ab9910b75de10e72
record_format	dspace
spelling	oai:doaj.org-article:7ecf6c59b1264893ab9910b75de10e722021-12-02T16:58:02ZAn integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy10.1038/s41467-019-10138-82041-1723https://doaj.org/article/7ecf6c59b1264893ab9910b75de10e722019-05-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-10138-8https://doaj.org/toc/2041-1723The HER2 monoclonal antibody, Trastuzumab, is the current standard treatment for HER2+ cancers but resistance to therapy occurs. Here, the authors show that activation of the PKR/eIF2α-P pathway exhibits anti-tumor effects in HER2+ cancer and is required for the response to Trastuzumab.Cedric DariniNour GhaddarCatherine ChabotGloria AssakerSiham SabriShuo WangJothilatha KrishnamoorthyMarguerite BuchananAdriana Aguilar-MahechaBassam AbdulkarimJean DeschenesJose TorresJosie Ursini-SiegelMark BasikAntonis E. KoromilasNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Cedric Darini Nour Ghaddar Catherine Chabot Gloria Assaker Siham Sabri Shuo Wang Jothilatha Krishnamoorthy Marguerite Buchanan Adriana Aguilar-Mahecha Bassam Abdulkarim Jean Deschenes Jose Torres Josie Ursini-Siegel Mark Basik Antonis E. Koromilas An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
description	The HER2 monoclonal antibody, Trastuzumab, is the current standard treatment for HER2+ cancers but resistance to therapy occurs. Here, the authors show that activation of the PKR/eIF2α-P pathway exhibits anti-tumor effects in HER2+ cancer and is required for the response to Trastuzumab.
format	article
author	Cedric Darini Nour Ghaddar Catherine Chabot Gloria Assaker Siham Sabri Shuo Wang Jothilatha Krishnamoorthy Marguerite Buchanan Adriana Aguilar-Mahecha Bassam Abdulkarim Jean Deschenes Jose Torres Josie Ursini-Siegel Mark Basik Antonis E. Koromilas
author_facet	Cedric Darini Nour Ghaddar Catherine Chabot Gloria Assaker Siham Sabri Shuo Wang Jothilatha Krishnamoorthy Marguerite Buchanan Adriana Aguilar-Mahecha Bassam Abdulkarim Jean Deschenes Jose Torres Josie Ursini-Siegel Mark Basik Antonis E. Koromilas
author_sort	Cedric Darini
title	An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
title_short	An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
title_full	An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
title_fullStr	An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
title_full_unstemmed	An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
title_sort	integrated stress response via pkr suppresses her2+ cancers and improves trastuzumab therapy
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/7ecf6c59b1264893ab9910b75de10e72
work_keys_str_mv	AT cedricdarini anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT nourghaddar anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT catherinechabot anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT gloriaassaker anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT sihamsabri anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT shuowang anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT jothilathakrishnamoorthy anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT margueritebuchanan anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT adrianaaguilarmahecha anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT bassamabdulkarim anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT jeandeschenes anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT josetorres anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT josieursinisiegel anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT markbasik anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT antonisekoromilas anintegratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT cedricdarini integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT nourghaddar integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT catherinechabot integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT gloriaassaker integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT sihamsabri integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT shuowang integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT jothilathakrishnamoorthy integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT margueritebuchanan integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT adrianaaguilarmahecha integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT bassamabdulkarim integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT jeandeschenes integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT josetorres integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT josieursinisiegel integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT markbasik integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy AT antonisekoromilas integratedstressresponseviapkrsuppressesher2cancersandimprovestrastuzumabtherapy
_version_	1718382394698891264

An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy

Ejemplares similares